FALLON LYNNETTE C 4

What Happened

Lynnette C. Fallon, a director of ClearPoint Neuro, was granted 12,820 restricted stock units (RSUs) on 2026-05-21. The award is reported as a derivative grant (transaction code A) with an exercise/acquisition price of $0.00, so the filing lists a total dollar amount of $0. Each RSU represents a contingent right to receive one share of CLPT common stock upon vesting.

Key Details

• Transaction date: 2026-05-21; Form 4 filed: 2026-05-26.
• Grant: 12,820 RSUs granted at $0.00 per RSU (total reported value $0).
• Transaction type/code: Award/Grant (A), derivative security (RSUs).
• Shares owned after transaction: not specified in the filing.
• Footnotes: (F1) Each RSU equals a contingent right to one share of CLPT common stock. (F2) RSUs vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day before the Company's 2027 annual meeting of stockholders.
• No indication in the filing that shares were immediately issued or sold; these units are contingent and vest in the future.

Context

RSU grants to directors are a common form of compensation and retention and do not represent an immediate purchase or sale of stock. Once the RSUs vest and are settled, they will convert into common shares and may dilute existing shareholders. For investors, grants are routine corporate compensation actions and should be viewed differently than open-market insider purchases or sales.